Valneva SE (VALN) Total Current Liabilities (2020 - 2026)
Valneva SE (VALN) posted quarterly Total Current Liabilities of $107.2 million for Q1 2026, down 11.28% year-on-year from $120.9 million in Q1 2025, and up 0.95% on a QoQ basis from $106.2 million in Q4 2025.
Valneva SE (VALN) Total Current Liabilities (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Total Current Liabilities for 7 consecutive years, with $107.2 million the latest figure, recorded in Q1 2026.
- Quarterly Total Current Liabilities fell 11.28% year-over-year to $107.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.2 million (down 11.28% YoY) and the FY2025 annual result came in at $106.2 million, down 18.54% from the prior year.
- Total Current Liabilities grew to $107.2 million in Q1 2026 per VALN's latest filing, from $106.2 million in the prior quarter.
- Over the last five years, Total Current Liabilities for VALN reached as high as $496.3 million in Q2 2022 and fell as low as $106.2 million in Q4 2025.
- A 5-year average of $223.9 million and a median of $171.2 million in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities tumbled 57.48% — and 2025, when it jumped 37.86%.
- Year by year, Total Current Liabilities stood at $315.7 million in 2022, then sank by 42.73% to $180.8 million in 2023, then decreased by 27.87% to $130.4 million in 2024, then decreased by 18.54% to $106.2 million in 2025, then rose by 0.95% to $107.2 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $107.2 million, $106.2 million, and $171.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 56.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 66.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.81 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 6.38 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 3.88 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.11 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.58 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 289.60 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | 107.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 107.22 Mn |
| Dec 31, 2025 | 106.21 Mn |
| Sep 30, 2025 | 171.24 Mn |
| Jun 30, 2025 | 143.00 Mn |
| Mar 31, 2025 | 120.85 Mn |
| Dec 31, 2024 | 130.39 Mn |
| Sep 30, 2024 | 124.21 Mn |
| Jun 30, 2024 | 116.63 Mn |
| Mar 31, 2024 | 132.10 Mn |
| Dec 31, 2023 | 180.78 Mn |
| Sep 30, 2023 | 248.25 Mn |
| Jun 30, 2023 | 274.30 Mn |
| Mar 31, 2023 | 299.58 Mn |
| Dec 31, 2022 | 315.66 Mn |
| Sep 30, 2022 | 425.84 Mn |
| Jun 30, 2022 | 496.29 Mn |
| Mar 31, 2022 | 413.37 Mn |
| Dec 31, 2021 | 419.88 Mn |
| Dec 31, 2020 | 200.13 Mn |